INPATIENT PROGRESS NOTE

Date: 2026-09-22

SUBJECTIVE

68-year-old male with COPD GOLD Stage III, hypertension, hyperlipidemia, former smoker presenting with 3-day history of worsening dyspnea, productive cough with yellow sputum, and fever.

OBJECTIVE

Vital Signs:

Temperature: 38.2°C
Heart Rate: 102 bpm
Respiratory Rate: 24/min
Blood Pressure: 138/84 mmHg
Oxygen Saturation: 88% on room air

Physical Examination:

Pulmonary: Diffuse wheezes bilaterally, increased tactile fremitus, crackles on auscultation
Cardiovascular: Tachycardic, regular rhythm
General: Appears in moderate respiratory distress

ASSESSMENT

This patient has a severe COPD exacerbation complicated by community-acquired pneumonia (CAP), requiring hospitalization and aggressive multimodal therapy. 1

This represents a severe exacerbation by GOLD criteria given the need for hospitalization, hypoxemia (SpO2 88% on room air), and clinical evidence of bacterial infection (fever, purulent sputum, increased tactile fremitus, crackles) 1. The presence of purulent yellow sputum with fever strongly suggests bacterial superinfection, which is a common trigger for COPD exacerbations and warrants antibiotic therapy 1.

Key Clinical Reasoning:

Severe classification justified by: Hospitalization requirement, hypoxemia, tachypnea (RR 24), and systemic signs of infection 1
CAP overlay likely: Fever, purulent sputum, increased tactile fremitus, and crackles suggest consolidation beyond simple COPD exacerbation 2, 3
Risk factors present: COPD patients have an 18-fold increased incidence of hospitalized CAP compared to non-COPD patients, with mortality rates of 5.6% in-hospital and 11.9% at 30 days 4
Gram-negative coverage consideration: COPD patients, particularly those with advanced disease, have increased risk for Pseudomonas aeruginosa and other gram-negative bacilli 3, 5

PLAN

1. Oxygen Therapy

Initiate controlled oxygen supplementation targeting SpO2 88-92% to correct hypoxemia while avoiding CO2 retention 1
Monitor arterial blood gas if clinical deterioration or altered mental status develops
Prepare for non-invasive ventilation (NIV) if respiratory failure worsens—NIV is the first-line ventilatory support for acute respiratory failure in COPD exacerbations 1

2. Bronchodilator Therapy

Short-acting beta-2 agonist (albuterol) with short-acting anticholinergic (ipratropium) via nebulizer or MDI with spacer every 4-6 hours 1
This combination is the recommended initial bronchodilator therapy for acute exacerbations 1
Avoid methylxanthines (theophylline) due to side effect profile without proven benefit 1

3. Systemic Corticosteroids

Prednisone 40 mg PO daily (or IV methylprednisolone 40-60 mg if unable to take PO) for 5 days 1
Systemic corticosteroids improve lung function, oxygenation, shorten recovery time, and reduce hospitalization duration 1
Monitor blood glucose closely given diabetes comorbidity

4. Antibiotic Therapy

Initiate empiric antibiotics immediately given purulent sputum, fever, and clinical evidence of bacterial pneumonia 1, 2
Recommended regimen: Respiratory fluoroquinolone (levofloxacin 750 mg IV/PO daily) OR combination therapy with ceftriaxone 1-2g IV daily PLUS azithromycin 500 mg IV/PO daily 2
Rationale: COPD patients with CAP have increased risk for Pseudomonas and gram-negative bacilli, particularly with advanced disease 3, 5. Fluoroquinolones provide excellent coverage for typical and atypical pathogens plus some gram-negative coverage
Antibiotics shorten recovery time, reduce early relapse, treatment failure, and hospitalization duration when indicated 1
Obtain blood cultures × 2, sputum culture and Gram stain before initiating antibiotics 2

5. Diagnostic Workup

Chest X-ray to confirm infiltrate, assess extent, rule out complications (effusion, cavitation)
Complete blood count with differential (assess for leukocytosis/leukopenia)
Basic metabolic panel (assess electrolytes, renal function)
Arterial blood gas if clinical deterioration or concern for hypercapnia
Blood cultures × 2 before antibiotics 2
Sputum Gram stain and culture before antibiotics 2

6. Monitoring

Continuous pulse oximetry with target SpO2 88-92%
Serial vital signs every 4 hours
Assess for clinical stability: Temperature normalization, heart rate <100 bpm, respiratory rate ≤24/min, SpO2 ≥90%, ability to eat, normal mentation 4
Time to clinical stability typically 2 days (IQR 1-4 days) in COPD patients with CAP 4
Monitor for treatment failure: Worsening hypoxemia, altered mental status, hemodynamic instability, or lack of improvement by 48-72 hours 2

7. Comorbidity Management

Continue home antihypertensive and lipid-lowering medications
Adjust diabetes medications given steroid therapy
Venous thromboembolism prophylaxis with subcutaneous heparin or enoxaparin given immobility risk

8. Discharge Planning (Initiate Early)

Initiate or optimize long-acting bronchodilator therapy (LABA/LAMA combination) before discharge 1
Smoking cessation counseling and pharmacotherapy if applicable (though listed as former smoker, confirm current status) 6
Pulmonary rehabilitation referral to improve functional capacity and reduce future exacerbations
Pneumococcal and influenza vaccination if not up to date 7
Exacerbation action plan education for early recognition and treatment
Follow-up within 2-4 weeks with primary care and pulmonology

PROGNOSIS & PITFALLS

Expected Course:

Median length of stay: 5 days (IQR 3-9 days) for COPD patients with CAP 4
Symptoms typically improve within 7-10 days, though 20% may not recover to baseline by 8 weeks 1

Critical Pitfalls to Avoid:

Excessive oxygen administration: Can precipitate hypercapnic respiratory failure in COPD patients—target SpO2 88-92%, not normalization 1
Delaying antibiotics: In presence of purulent sputum and fever, antibiotics are indicated and delay worsens outcomes 1, 2
Inadequate gram-negative coverage: COPD patients have increased risk for Pseudomonas and gram-negative organisms, particularly with advanced disease or recent steroid use 3, 5
Failure to assess for treatment failure at 48-72 hours: Nonresponse requires reevaluation for resistant organisms, alternative diagnoses (PE, CHF, malignancy), or complications 2
Omitting discharge optimization: Failure to initiate long-acting bronchodilators before discharge increases risk of readmission 1

Mortality Risk:

In-hospital mortality: 5.6%
30-day mortality: 11.9%
1-year mortality: 33.0% 4

This patient requires close monitoring for respiratory failure given hypoxemia and tachypnea, with low threshold for escalation to NIV if deterioration occurs.

Have a follow-up question?